Frontiers in Pharmacology (May 2023)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases

  • Chunkun Yang,
  • Qingquan Pan,
  • Kui Ji,
  • Zhuang Tian,
  • Hongyuan Zhou,
  • Shuanghong Li,
  • Chuanchao Luo,
  • Jun Li

DOI
https://doi.org/10.3389/fphar.2023.1187910
Journal volume & issue
Vol. 14

Abstract

Read online

Cardiovascular disease is a global health problem. Astragaloside IV (AS-IV) is a saponin compound extracted from the roots of the Chinese herb Astragalus. Over the past few decades, AS-IV has been shown to possess various pharmacological properties. It can protect the myocardium through antioxidative stress, anti-inflammatory effects, regulation of calcium homeostasis, improvement of myocardial energy metabolism, anti-apoptosis, anti-cardiomyocyte hypertrophy, anti-myocardial fibrosis, regulation of myocardial autophagy, and improvement of myocardial microcirculation. AS-IV exerts protective effects on blood vessels. For example, it can protect vascular endothelial cells through antioxidative stress and anti-inflammatory pathways, relax blood vessels, stabilize atherosclerotic plaques, and inhibit the proliferation and migration of vascular smooth muscle cells. Thus, the bioavailability of AS-IV is low. Toxicology indicates that AS-IV is safe, but should be used cautiously in pregnant women. In this paper, we review the mechanisms of AS-IV prevention and treatment of cardiovascular diseases in recent years to provide a reference for future research and drug development.

Keywords